Melucci v. Corcept Therapeutics Incorporated

District Court, N.D. California·Decided October 7, 2019·No. 3:19-cv-01372·Unknown

Opinion

NORTHERN DISTRICT OF CALIFORNIA SAN JOSE DIVISION

NICHOLAS MELUCCI, Case No. 19-CV-01372-LHK

Plaintiff, ORDER APPOINTING LEAD PLAINTIFF AND LEAD COUNSEL v. Re: Dkt. Nos. 15, 17, 24, 29, 32, 58 INCORPORATED, et al., Defendants.

This case is a putative securities class action brought against Defendant Corcept Therapeutics Incorporated (“Corcept”); its President and Chief Executive Officer, Joseph K. Belanoff; and its Chief Financial Officer, Charles Robb. Plaintiffs in this action consist of “persons and entities that purchased or otherwise acquired Corcept securities between August 2, 2017 and February 5, 2019, inclusive (the ‘Class Period’).” ECF No. 1 (“Compl.”) ¶ 1. Before the Court are four outstanding Motions for Appointment as Lead Plaintiff and Approval of Lead Counsel. Corcept is a “pharmaceutical company that purports to develop medications to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effect of cortisol.” Id. ¶ 2. Plaintiffs allege that, throughout the Class Period, Corcept’s “positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis,” in light of the following: (1) that the Company had improperly paid doctors to promote its drug Korlym; (2) that the Company aggressively promoted Korlym for off-label uses; (3) that the Company’s sole specialty pharmacy was a related party; (4) that the Company artificially inflated its revenue and sales using illicit sales practices through a related party; (5) that such practices are reasonably likely to lead to regulatory scrutiny. Id. at ¶ 8. Plaintiffs claim that, as the public became aware of the truth, the revelations gradually impacted the share price, culminating in “significant losses and damages.” See id. ¶¶ 3–9. After the instant suit was filed and notice publicized regarding the pendency of this case, the Court received five motions to appoint lead plaintiff and approval of lead counsel. The first is Plaintiff Robert Baffa’s motion for appointment of Baffa as lead plaintiff and approval of Baffa’s selection of counsel. ECF No. 15. The second motion was filed by Plaintiffs Ferraro Family Foundation, Inc. and James L. Ferraro (collectively, the “Ferraro Group”), requesting appointment of the group as lead plaintiff and approval of its selection of counsel. ECF No. 17. The third is Plaintiff Bucks County Employees Retirement Fund’s (“BCERF”) motion for appointment of BCERF as lead plaintiff and approval of its selection of counsel. ECF No. 24. The fourth is Plaintiff Nicholas Melucci’s motion for appointment of Melucci as lead plaintiff and approval of its selection of counsel. ECF No. 29. The fifth is Plaintiff Nova Scotia Health Employees Pension Plan’s (“NSHEPP”) motion for appointment of NSHEPP as lead plaintiff and approval of its selection of counsel. ECF No. 32. Baffa withdrew his motion, ECF No. 44, as did BCERF, ECF No. 42. The Court denied a stipulation by the Ferraro Group and NSHEPP proposing a co-lead plaintiff structure, ECF No. 55, after which BCERF filed a response purporting to renew its motion to serve as lead plaintiff and for approval of its choice of counsel.1 ECF No. 58. 1 Following the Court’s denial of the joint stipulation, the Ferraro Group and NSHEPP filed letter “responses” to the denial. See ECF Nos. 56, 57. The parties are advised that the Court does not allow such filings and will not consider them in the future. The Private Securities Litigation Reform Act (“PSLRA”), 15 U.S.C. § 78u–4, governs the selection of a lead plaintiff in private securities class actions. In the PSLRA’s own words, this plaintiff is to be the “most capable of adequately representing the interests of class members.” 15 U.S.C. § 78u–4(a)(3)(B)(i). Under the PSLRA, a three-step process determines the lead plaintiff. In re Cavanaugh, 306 F.3d 726, 729 (9th Cir. 2002). First, the first plaintiff to file an action governed by the PSLRA must publicize the pendency of the action, the claims made, and the purported class period “in a widely circulated national business-oriented publication or wire service.” 15 U.S.C. § 78u–4(a)(3)(A)(i)(I). This notice must state that “any member of the purported class may move the court to serve as lead plaintiff.” 15 U.S.C. § 78u–4(a)(3)(A)(i)(II). Second, the court must select the presumptive lead plaintiff. See In re Cavanaugh, 306 F.3d at 729–30 (citing 15 U.S.C. § 78u–4(a)(3)(B)(iii)(I)). In order to determine the presumptive lead plaintiff, “the district court must compare the financial stakes of the various plaintiffs and determine which one has the most to gain from the lawsuit.” Id. at 730 (footnote omitted). Once the district court identifies the plaintiff with the most to gain, the district court must determine whether that plaintiff, based on the information he provides, “satisfies the requirements of Federal Rule of Civil Procedure 23(a), in particular those of ‘typicality’ and ‘adequacy.’” Id. If he does, that plaintiff becomes the presumptive lead plaintiff. Id. If not, the court turns to the plaintiff with the next-largest financial stake and determines whether that plaintiff satisfies the requirements of Rule 23. Id. The court repeats this process until it selects a presumptive lead plaintiff. Id. Third, those plaintiffs not selected as the presumptive lead plaintiff may “rebut the presumptive lead plaintiff's showing that it satisfies Rule 23’s typicality and adequacy requirements.” Id. (citing 15 U.S.C. § 78u–4(a)(3)(B)(iii)(II)). This is done by showing that the presumptive lead plaintiff either “will not fairly and adequately protect the interests of the class” or “is subject to unique defenses that render such plaintiff incapable of adequately representing the class.” 15 U.S.C. § 78u–4(a)(3)(B)(iii)(II)(aa)-(bb). If the court determines that the presumptive lead plaintiff does not meet the typicality or adequacy requirement, then it must return to step two, select a new presumptive lead plaintiff, and again allow the other plaintiffs to rebut the new presumptive lead plaintiff’s showing. In re Cavanaugh, 306 F.3d at 731. The court repeats this process “until all challenges have been exhausted.” Id. Under the PSLRA, the lead plaintiff is given the right, subject to court approval, to select counsel to represent the class. 15 U.S.C. § 78u–4(a)(3)(B)(v). “[T]he district court should not reject a lead plaintiff's proposed counsel merely because it would have chosen differently.” Cohen v. U.S. Dist. Court, 586 F.3d 703, 711 (9th Cir. 2009). “[I]f the lead plaintiff has made a reasonable choice of counsel, the district court should generally defer to that choice.” Id. at 712. In conformity with the procedure established by the PSLRA and the Ninth Circuit, the Court will determine which of the moving plaintiffs is presumptively the “most adequate plaintiff,” 15 U.S.C. § 78u-4(a)(3)(B)(iii)(I), and then whether any of the other purported class members have rebutted th

Free access — add to your briefcase to read the full text and ask questions with AI

Melucci v. Corcept Therapeutics Incorporated, (N.D. Cal. 2019).

Melucci v. Corcept Therapeutics Incorporated (Melucci v. Corcept Therapeutics Incorporated) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Staton v. Boeing Co.
327 F.3d 938 (Ninth Circuit, 2003)
Monier v. Apfel
22 F. Supp. 2d 1035 (E.D. Missouri, 1998)
In Re Olsten Corp. Securities Litig.
3 F. Supp. 2d 286 (E.D. New York, 1998)
In re Diamond Foods, Inc., Securities Litigation
281 F.R.D. 405 (N.D. California, 2012)
Schwartz v. Harp
108 F.R.D. 279 (C.D. California, 1985)